Taysha Gene Therapies, Inc. (TSHA) · Insider trading
What Taysha Gene Therapies's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$6.66M
3 insiders, 46% under a plan
Net, 12 months
−$6.66M
bought less sold
Latest filing
2026-07-10
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Nagendran SukumarDirector, President and Head of R&D | – | $6.13M | 9 | 2026-07-10 | 936,410 |
| Manning Paul B10% owner | $2.06M | – | 1 | 2025-05-30 | – |
| Nolan Sean P.Director, Chief Executive Officer | – | $840,196 | 2 | 2026-01-26 | 2,908,257 |
| Alam KamranCHIEF FINANCIAL OFFICER | – | $647,822 | 4 | 2026-02-04 | 1,442,131 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | Nagendran SukumarDirector, President and Head of R&D | Saleplan | 200,000 | 6.24 | $1.25M | 936,410 | Form 4 |
| 2026-04-10 | Nagendran SukumarDirector, President and Head of R&D | Saleplan | 200,000 | 4.46 | $892,000 | 1,136,410 | Form 4 |
| 2026-02-04 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 1,655 | 4.52 | $7,481 | 1,442,131 | Form 4 |
| 2026-01-26 | Nolan Sean P.Director, Chief Executive Officer | Sale | 41,312 | 4.61 | $190,448 | 2,908,257 | Form 4 |
| 2026-01-26 | Nagendran SukumarDirector, President and Head of R&D | Sale | 26,918 | 4.61 | $124,092 | 1,317,389 | Form 4 |
| 2026-01-26 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 23,849 | 4.61 | $109,944 | 1,443,786 | Form 4 |
| 2026-01-23 | Nolan Sean P.Director, Chief Executive Officer | Sale | 136,789 | 4.75 | $649,748 | 2,949,569 | Form 4 |
| 2026-01-23 | Nagendran SukumarDirector, President and Head of R&D | Sale | 89,132 | 4.75 | $423,377 | 1,344,307 | Form 4 |
| 2026-01-23 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 78,968 | 4.75 | $375,098 | 1,467,635 | Form 4 |
| 2026-01-12 | Nagendran SukumarDirector, President and Head of R&D | Saleplan | 200,000 | 4.71 | $942,000 | 1,006,439 | Form 4 |
| 2025-12-01 | Nagendran SukumarDirector, President and Head of R&D | Sale | 260,047 | 4.51 | $1.17M | 1,006,439 | Form 4 |
| 2025-11-28 | Nagendran SukumarDirector, President and Head of R&D | Sale | 110,125 | 4.75 | $523,094 | 1,006,439 | Form 4 |
| 2025-09-10 | Nagendran SukumarDirector, President and Head of R&D | Saleplan | 200,000 | 3.23 | $646,000 | 1,006,439 | Form 4 |
| 2025-08-21 | Alam KamranCHIEF FINANCIAL OFFICER | Sale | 54,491 | 2.85 | $155,299 | 1,187,603 | Form 4 |
| 2025-08-21 | Nagendran SukumarDirector, President and Head of R&D | Sale | 57,054 | 2.85 | $162,604 | 1,165,289 | Form 4 |
| 2025-05-30 | Manning Paul B10% owner | Buyindirect | 750,000 | 2.75 | $2.06M | 2,841,704 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
14 × grant or award7 × option exercise1 × shares withheld for tax
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-01 | Donenberg Phillip B.Director | Grant or award A | +21,335 | – | 241,289 | Form 4 |
| 2026-06-01 | Stalfort John A IIIDirector | Grant or award A | +21,335 | – | 1,176,559 | Form 4 |
| 2026-06-01 | Sepp-Lorenzino LauraDirector | Grant or award A | +21,335 | – | 127,178 | Form 4 |
| 2026-06-01 | Long Alison SDirector | Grant or award A | +21,335 | – | 127,178 | Form 4 |
| 2026-04-10 | Nagendran SukumarDirector, President and Head of R&D | Option exercise M | +19,021 | 1.71 | 1,336,410 | Form 4 |
| 2026-01-12 | Nolan Sean P.Director, Chief Executive Officer | Grant or award A | +1,008,000 | – | 3,086,358 | Form 4 |
| 2026-01-12 | Nagendran SukumarDirector, President and Head of R&D | Option exercise M | +111,324 | 0.70 | 1,117,763 | Form 4 |
| 2026-01-12 | Nagendran SukumarDirector, President and Head of R&D | Option exercise M | +88,676 | 1.71 | 1,206,439 | Form 4 |
| 2026-01-12 | Nagendran SukumarDirector, President and Head of R&D | Grant or award A | +427,000 | – | 1,433,439 | Form 4 |
| 2026-01-12 | Alam KamranCHIEF FINANCIAL OFFICER | Grant or award A | +359,000 | – | 1,546,603 | Form 4 |
| 2025-12-01 | Nagendran SukumarDirector, President and Head of R&D | Option exercise M | +260,047 | 1.71 | 1,266,486 | Form 4 |
| 2025-11-28 | Nagendran SukumarDirector, President and Head of R&D | Option exercise M | +70,172 | 0.70 | 1,076,611 | Form 4 |
| 2025-11-28 | Nagendran SukumarDirector, President and Head of R&D | Option exercise M | +39,953 | 1.71 | 1,116,564 | Form 4 |
| 2025-09-10 | Nagendran SukumarDirector, President and Head of R&D | Option exercise M | +41,150 | 0.70 | 1,206,439 | Form 4 |
| 2025-06-02 | Sepp-Lorenzino LauraDirector | Grant or award A | +56,623 | – | 105,843 | Form 4 |
| 2025-06-02 | Long Alison SDirector | Grant or award A | +56,623 | – | 105,843 | Form 4 |
| 2025-06-02 | Donenberg Phillip B.Director | Grant or award A | +56,623 | – | 219,954 | Form 4 |
| 2025-06-02 | Stalfort John A IIIDirector | Grant or award A | +56,623 | – | 1,155,224 | Form 4 |
| 2025-03-11 | Alam KamranCHIEF FINANCIAL OFFICER | Shares withheld for tax F | −29,843 | 1.69 | 1,242,094 | Form 4 |
| 2025-01-02 | Alam KamranCHIEF FINANCIAL OFFICER | Grant or award A | +431,000 | – | 1,271,937 | Form 4 |
| 2025-01-02 | Nagendran SukumarDirector, President and Head of R&D | Grant or award A | +324,500 | – | 1,222,343 | Form 4 |
| 2025-01-02 | Nolan Sean P.Director, Chief Executive Officer | Grant or award A | +892,500 | – | 2,078,358 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.